HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options. (Q38055705)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23100110%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23100110%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23100110%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Micol S Rothman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23100110%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

1 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23100110%20AND%20SRC:MED&resulttype=core&format=json

Current osteoporosis reports

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23100110%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23100110%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23100110%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

270-277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23100110%20AND%20SRC:MED&resulttype=core&format=json

Survival of persons with and without HIV infection in Denmark, 1995-2005.

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Reduced bone mineral density in HIV-infected patients: prevalence and associated factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Bone disease in HIV infection: a practical review and recommendations for HIV care providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Increased risk of fragility fractures among HIV infected compared to uninfected male veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

HIV: inflammation and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

The immune system and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Continuous antiretroviral therapy decreases bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Role of T cells in ovariectomy induced bone loss--revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Use of dual-energy x-ray absorptiometry (DXA) scans in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Premature decline of serum total testosterone in HIV-infected men in the HAART-era

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Therapeutic options for low bone mineral density in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Body composition changes after switching from protease inhibitors to raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-012-0125-0

Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23100110

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Depression, Testosterone concentration, sexual dysfunction and methadone use among men with hypogonadism and HIV Infection

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23100110

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23100110